Nasdaq

FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy

The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathy Spinal cord stimulation is proven to be more effective ...
WFMZ-TV

Global Spinal Cord Stimulation (SCS) Market 2019-2023: Rise in Adoption of Surgical Robots / Proclaim XR / 7D Surgical System / Attempts by Major Players to Strengthen Presence ...

DUBLIN, Dec. 9, 2019 /PRNewswire/ -- The "Global Spinal Cord Stimulation (SCS) Market: Size, Trends & Forecasts (2019-2023)" report has been added to ResearchAndMarkets.com's offering. Global Spinal ...
Healio

FDA approves spinal cord stimulation system for chronic, nonsurgical back pain

Please provide your email address to receive an email when new articles are posted on . Abbott has announced the FDA expanded the indication of its BurstDR spinal cord stimulation devices for treating ...
Monthly Prescribing Reference

Abbott’s SCS Systems Approved for Nonsurgical Refractory Back Pain

Credit: Shutterstock. Study participants suffered from chronic back pain for an average of 12.8 years. The Food and Drug Administration (FDA) has expanded the approval of Abbott’s spinal cord ...